119 related articles for article (PubMed ID: 12182847)
1. Peptide inhibitors of CDK2-cyclin A that target the cyclin recruitment-site: structural variants of the C-terminal Phe.
Atkinson GE; Cowan A; McInnes C; Zheleva DI; Fischer PM; Chan WC
Bioorg Med Chem Lett; 2002 Sep; 12(18):2501-5. PubMed ID: 12182847
[TBL] [Abstract][Full Text] [Related]
2. Specificity determinants of recruitment peptides bound to phospho-CDK2/cyclin A.
Lowe ED; Tews I; Cheng KY; Brown NR; Gul S; Noble ME; Gamblin SJ; Johnson LN
Biochemistry; 2002 Dec; 41(52):15625-34. PubMed ID: 12501191
[TBL] [Abstract][Full Text] [Related]
3. Stoichiometry of cyclin A-cyclin-dependent kinase 2 inhibition by p21Cip1/Waf1.
Adkins JN; Lumb KJ
Biochemistry; 2000 Nov; 39(45):13925-30. PubMed ID: 11076534
[TBL] [Abstract][Full Text] [Related]
4. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases.
Brown NR; Noble ME; Endicott JA; Johnson LN
Nat Cell Biol; 1999 Nov; 1(7):438-43. PubMed ID: 10559988
[TBL] [Abstract][Full Text] [Related]
5. Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange.
Kontopidis G; Andrews MJ; McInnes C; Cowan A; Powers H; Innes L; Plater A; Griffiths G; Paterson D; Zheleva DI; Lane DP; Green S; Walkinshaw MD; Fischer PM
Structure; 2003 Dec; 11(12):1537-46. PubMed ID: 14656438
[TBL] [Abstract][Full Text] [Related]
6. Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate.
Davies TG; Tunnah P; Meijer L; Marko D; Eisenbrand G; Endicott JA; Noble ME
Structure; 2001 May; 9(5):389-97. PubMed ID: 11377199
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex.
Russo AA; Jeffrey PD; Patten AK; Massagué J; Pavletich NP
Nature; 1996 Jul; 382(6589):325-31. PubMed ID: 8684460
[TBL] [Abstract][Full Text] [Related]
8. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4.
Park H; Yeom MS; Lee S
Chembiochem; 2004 Dec; 5(12):1662-72. PubMed ID: 15505811
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.
De Azevedo WF; Mueller-Dieckmann HJ; Schulze-Gahmen U; Worland PJ; Sausville E; Kim SH
Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2735-40. PubMed ID: 8610110
[TBL] [Abstract][Full Text] [Related]
10. X-ray crystallographic studies of CDK2, a basis for cyclin-dependent kinase inhibitor design in anti-cancer drug research.
Furet P
Curr Med Chem Anticancer Agents; 2003 Jan; 3(1):15-23. PubMed ID: 12678911
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex.
Legraverend M; Tunnah P; Noble M; Ducrot P; Ludwig O; Grierson DS; Leost M; Meijer L; Endicott J
J Med Chem; 2000 Apr; 43(7):1282-92. PubMed ID: 10753466
[TBL] [Abstract][Full Text] [Related]
12. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.
Mettey Y; Gompel M; Thomas V; Garnier M; Leost M; Ceballos-Picot I; Noble M; Endicott J; Vierfond JM; Meijer L
J Med Chem; 2003 Jan; 46(2):222-36. PubMed ID: 12519061
[TBL] [Abstract][Full Text] [Related]
13. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2.
Lawrie AM; Noble ME; Tunnah P; Brown NR; Johnson LN; Endicott JA
Nat Struct Biol; 1997 Oct; 4(10):796-801. PubMed ID: 9334743
[TBL] [Abstract][Full Text] [Related]
15. Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex.
Yin MB; Guo B; Panadero A; Frank C; Wrzosek C; Slocum HK; Rustum YM
Exp Cell Res; 1999 Feb; 247(1):189-99. PubMed ID: 10047461
[TBL] [Abstract][Full Text] [Related]
16. Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors.
Rossi KA; Markwalder JA; Seitz SP; Chang CH; Cox S; Boisclair MD; Brizuela L; Brenner SL; Stouten PF
J Comput Aided Mol Des; 2005 Feb; 19(2):111-22. PubMed ID: 16075305
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.
Arris CE; Boyle FT; Calvert AH; Curtin NJ; Endicott JA; Garman EF; Gibson AE; Golding BT; Grant S; Griffin RJ; Jewsbury P; Johnson LN; Lawrie AM; Newell DR; Noble ME; Sausville EA; Schultz R; Yu W
J Med Chem; 2000 Jul; 43(15):2797-804. PubMed ID: 10956187
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for chemical inhibition of CDK2.
Kim SH; Schulze-Gahmen U; Brandsen J; de Azevedo Júnior WF
Prog Cell Cycle Res; 1996; 2():137-45. PubMed ID: 9552391
[TBL] [Abstract][Full Text] [Related]
19. Alternative binding modes of an inhibitor to two different kinases.
De Moliner E; Brown NR; Johnson LN
Eur J Biochem; 2003 Aug; 270(15):3174-81. PubMed ID: 12869192
[TBL] [Abstract][Full Text] [Related]
20. The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A.
Luciani MG; Hutchins JR; Zheleva D; Hupp TR
J Mol Biol; 2000 Jul; 300(3):503-18. PubMed ID: 10884347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
